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The effect of linagliptin treatment  
on gut microbiota in patients with  
HNF1A-MODY or type 2 diabetes  
— a preliminary cohort study
ABSTRACT
Introduction. Many studies have evaluated the rela-
tionship between diabetes and microbiota. In animal 
models, the dipeptidyl peptidase-4 inhibitors altered 
the gut microbiota. We investigated whether linaglip-
tin alters the gastrointestinal flora in humans. 
Materials and methods. This prospective cohort study 
enrolled 24 patients: 5 patients with maturity onset 
diabetes of the young associated with HNF1A mutation 
and 19 patients with type 2 diabetes mellitus. Stool 
samples were collected at baseline and 4 weeks after 
treatment intensification with either linagliptin or 
a sulphonylurea alongside current treatment. Faecal 
16S rRNA was analysed by next-generation sequencing.
Results. Nine patients initiated linagliptin whereas 
15 patients initiated or increased the dose of a sul-
phonylurea. After linagliptin treatment, we did not 
observe changes in taxa in L2–L7 based on analysis of 
composition of microbiomes (ANCOM). The same held 
true for pairwise alpha diversity (Shannon diversity, 
p = 0.59; Pielou’s measure of evenness, p = 0.68; and 
observed operational taxonomic units [OTUs], p = 0.77) 
and beta diversity distances (unweighted UniFrac, 
p = 0.99; weighted UniFrac, p = 0.93; Bray-Curtis, 
p = 0.98; and Jaccard, p = 0.99). Similarly, after sulpho-
nylurea intensification, we did not observe changes in 
taxa in L2–L7 in ANCOM, nor were there changes in alpha 
diversity (Shannon diversity, p = 0.19; Pielou’s measure 
of evenness, p = 0.21; and observed OTUs, p = 0.42) 
or beta diversity distances (unweighted UniFrac, 
p = 0.99; weighted UniFrac, p = 0.99; Bray-Curtis, 
p = 1; and Jaccard, p = 0.99).
Conclusion. We did not observe changes in colonic 
microbiota 4 weeks after addition of linagliptin to 
current diabetes treatment. Further studies are re-
quired to determine whether linagliptin influences the 
colonic microbiota in humans. (Clin Diabetol 2019; 8, 
6: 263–270)
Key words: diabetes, HNF 1 alpha, linagliptin, 
microflora, sulfonylurea
Introduction
Despite extensive research in type 2 diabetes 
(T2DM), the pathogenesis of the condition and the fac-
tors underpinning disease progression and therapeutic 
response remain incompletely understood [1]. Estab-
lished risk factors for T2DM include obesity, sedentary 
lifestyle, older age and strong family history of the 
disease [2]. Genome-wide association studies have pro-
vided valuable insights into the genetic predisposition 
to various conditions, including T2DM, but have had 
Clinical Diabetology 2019, Vol. 8, No. 6
264
limited success in explaining the heritability of complex 
diseases [3, 4]. To account for this unexplained heri - 
tability, a role has been proposed for gene–environment 
interactions, including gastrointestinal bacterial flora 
or nutrition/medication-related alterations in gastroin-
testinal hormone activity [3].
Many recent studies have focused on the relation-
ship between T2DM and gastrointestinal bacterial flora 
[5]. For example, differences in microbiota have been 
demonstrated between healthy subjects and patients 
with monogenic forms of diabetes [6, 7]. Obesity, 
a risk factor for T2DM, has also been associated with 
alterations in gut microbiota [8]; however, body mass 
index-independent differences in bacterial flora have 
been observed in patients with T2DM compared with 
healthy subjects [9]. Some changes in microbiota pre-
viously shown in patients with T2DM versus healthy 
individuals have been attributed to metformin use [10].
Dipeptidyl peptidase-4 (DPP-4) inhibitors are 
a well-established class of medications used widely in 
the management of T2DM [11]. Of interest, it has been 
shown that at least three DPP-4 inhibitors (sitagliptin, 
saxagliptin and vildagliptin) may alter the structure of 
gastrointestinal flora in animal models [12–16]. Some 
other antidiabetic medications, including liraglutide and 
acarbose, are also postulated to modify gut microbiota 
[12]. However, it remains unclear whether these effects 
on the microbiota influence therapeutic response.
The DPP-4 inhibitor linagliptin has not been studied 
in regard to gut microbiota and is the only member of 
the drug class that is primarily eliminated as the pa-
rent compound in faeces (95%) [17]. The aim of this 
prospective study was to compare the colonic bacterial 
flora structure before and after the addition of lina-
gliptin to current treatment in patients with T2DM or 
maturity onset diabetes of the young associated with 
HNF1A mutation (HNF1A-MODY). 
Materials and methods
Study setting and eligibility
The cohort study was conducted between 2013 
and 2015 at the Department of Metabolic Diseases, 
Jagiellonian University Medical College, Krakow, Po-
land and the University Hospital, Krakow, Poland, in 
collaboration with the Center for Medical Genomics 
(OMICRON) and Department of Microbiology, Jagiel-
lonian University Medical College, Krakow, Poland. 
Patients treated in our Outpatient Clinic and volunteers 
took a part in a study. The cohort has been described 
in detail previously [7]. Briefly, the study enrolled men 
and women aged 18–65 years with T2DM or HNF1A-
-MODY receiving metformin alone or metformin plus 
a sulphonylurea (SU) at or below the submaximal 
dose, or (for patients with HNF1A-MODY only) insulin 
therapy. Patients were also required to have poorly con-
trolled glycaemia (glycosylated haemoglobin [HbA1c] 
> 7% or > 53 mmol/mol) and no advanced, chronic 
complications of diabetes. Confirmed patient readiness 
to cooperate with the research centre was required for 
study participation. All participants declared not using 
antibiotics 4 weeks before stool sample collection. The 
exclusion criteria were as follows: lack of consent to 
participate in the study, withdrawal during the study, 
taking antibiotics or probiotics up to 30 days before 
the sample collection, confirmed infection of the gas-
trointestinal tract, chronic inflammatory bowel disease 
of unknown etiology, active cancer (especially of the 
gastrointestinal tract), immunodeficiency, features of 
liver damage (with the exception of nonalcoholic fatty 
liver transaminase levels less than three times the upper 
limit of the normal level). The study received approval 
from the Jagiellonian University Ethics Committee. All 
participants provided written informed consent in ac-
cordance with the Declaration of Helsinki.
Laboratory investigations
Blood samples were obtained from all patients. 
HbA1c, triglycerides, total cholesterol, low-density 
lipoprotein cholesterol, high-density lipoprotein cho-
lesterol, C-reactive protein, aspartate transaminase 
and alanine transaminase were assessed by standard 
laboratory techniques. 
Treatment and follow-up 
Diabetes therapy was intensified in all patients. 
In the linagliptin group, patients were prescribed lina-
gliptin in addition to current treatment, while in the 
control group (SU group), the dose of a current SU was 
increased or a new SU was initiated alongside current 
treatment. Treatment allocation was not randomised, 
but was instead based on local guidelines and long-term 
drug affordability for the patient (given the substantially 
greater cost of DPP-4 inhibitors than SU in Poland). Pa-
tients were asked to avoid changing their dietary habits 
and level of physical activity during the study.
Stool samples were collected from all patients 
before and 4 weeks after treatment intensification. 
In 21 patients, information from blinded continuous 
glucose monitoring (iPro2, Medtronic, Dublin, Ireland) 
was obtained from 1 week before and 3 weeks after 
treatment intensification (i.e., in the fourth week of 
intensified treatment).
RNA isolation and 16S metagenomic sequencing
Bacterial RNA was isolated using Genomic Mini 
AX Stool Spin (A&A Biotechnology, Gdynia, Poland), 
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modified to include enzymatic treatment (lysozyme, 
lysostaphin and lyticase) and a bead-beating step. 
Libraries were prepared according to the Illumina 




prep-guide-15044223-b.pdf). Briefly, universal external 
primers were used to amplify regions V3 and V4 of the 
16S rRNA. After the polymerase chain reaction clean-
up, samples were indexed, cleaned and pooled. Finally, 
10 pM libraries with 10% PhiX Spike-In were sequenced 
on Illumina MiSeq (Illumina, Inc., San Diego, CA, US) 
using the V3 sequencing kit (300 bp paired-end reads).
Sequencing data analysis 
Samples were processed and analysed using the 
Quantitative Insights Into Microbial Ecology 2 (QIIME2, 
version 2018.11) [18] custom pipeline. Briefly, the qual-
ity of demultiplexed paired-end reads from MiSeq (2 × 
300 bp) was evaluated and the reads were trimmed to 
remove primers and poor-quality bases with cutadapt 
[19]. Trimmed sequences were denoised and joined 
with DADA2 [20]. Next, closed-reference clustering 
of features [21] and reference-based chimera filtering 
were performed using vsearch [22] and the Greengenes 
database at 99% similarity [23]. Generated operational 
taxonomic units (OTUs) were assigned to taxonomy us-
ing a naive Bayes classifier [24], which was pre-trained 
on the sequenced target RNA regions. For further 
analysis, we included only features occurring in at least 
three samples that had more than 20 total reads. The 
bacterial composition was analysed at phylum, order, 
family, genus and species levels. Filtered feature ta-
bles were used to generate the trees for phylogenetic 
diversity analyses. Rarefaction curve analysis was used 
to estimate the completeness of microbial community 
sampling. We also computed default alpha and beta 
diversity metrics and generated principal coordinates 
analysis (PCoA) plots for each of the beta diversity met-
rics using Emperor [25]. Group significance between al-
pha and beta diversity indices were calculated with the 
QIIME2 longitudinal pairwise-differences plugin using 
the t-test. Correlations with alpha diversity indices were 
calculated with the QIIME2 plugin using Spearman 
correlation. Differential abundance between groups 
at each taxonomic level was tested using analysis of 
composition of microbiomes (ANCOM) [26].
Statistical analysis
The reported p-values were not corrected for 
multiple testing. Continuous variables are presented 
as medians and interquartile ranges (IQRs), whereas 
categorical variables are expressed as counts with 
percentages. Groups were compared with the Mann-
Whitney U test, Fisher’s exact test and Wilcoxon test 
using Statistica 13 software (StatSoft Inc., Tulsa, OK, 
US). Post-hoc power analysis was performed in package 
R [27], v.3.5.1. Power was set at 0.8 and the significance 
level (alpha level) was set at 0.05.
Results
Patient population
A total of 60 patients were initially interviewed, 
of whom 29 patients with T2DM and 11 patients with 
HNF1A-MODY agreed to participate and follow the 
study protocol. Of this group, we enrolled 24 patients 
who met the eligibility criteria.
Five patients had HNF1A-MODY and 19 patients 
had T2DM. The median age was 60 years. Median 
HbA1c was 66 mmol/mol (8.2%), with an IQR of 62–70 
mmol/mol (7.8–8.6%). In 5 patients with T2DM and 4 
patients with HNF1A-MODY, linagliptin was added to 
current treatment (linagliptin group). In 1 patient with 
HNF1A-MODY and 14 patients with T2DM, an SU was 
initiated or the dose of a current SU was increased ac-
cording to local guidelines (SU group). There were no 
differences in patient characteristics between groups 
at baseline (Table 1). 
16S rRNA sequencing
Sequencing analysis of the 48 samples provided 
a mean 57,145 reads per sample (median, 52,547). The 
best sample contained 142,914 read pairs, while the 
worst contained 10,608. OTU picking resulted in 570, 
with total frequency of 2,742,964 features. 
Bacterial profile at baseline
In the linagliptin and SU groups, respectively, 
baseline bacterial profiles with an abundance of 
> 1% at the phylum level were Actinobacteria (6.23% 
vs. 10.98%), Bacteroidetes (1.15% vs. 2.02%), Firmi-
cutes (88.42% vs. 78.83%), Proteobacteria (1.83% vs. 
2.81%) Verrucomicrobia (2.13% vs. 5.09%) and ‘other’ 
(0.24% vs. 0.28%; Figure 1A). At the class level, base-
line bacterial profiles included Actinobacteria (1.27% 
vs. 4.50%), Coriobacteriia (4.96% vs. 6.47%), Bacte-
roidia (1.15% vs. 2.02%), Bacilli (2.21% vs. 2.39%), 
Clostridia (81.12% vs. 71.89%), Erysipelotrichi (5.09% 
vs. 4.55%), Gammaproteobacteria (1.56% vs. 2.75%), 
Verrucomicrobiae (2.13% vs. 5.09%) and ‘other’ (0.50% 
vs. 0.33%; Figure 1B).
Comparing the SU group with the linagliptin 
group prior to intensification, we observed a single 
significantly increased abundance at the class level (for 
Actinobacteria; centred log-ratio [clr]= 2.57, W = 5). 
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Table 1. Patient characteristics at baseline
Variable* All patients  
(n = 24)





Male sex, n (%) 13 (54.2) 5 (55.6) 8 (53.3) 0.42
Age (years) 60 (55.5–62.5) 55 (50–61) 60 (57–63) 0.16
Duration of diabetes (years) 5 (1.9–9) 11 (1.3–23) 5 (2.5–6) 0.24
BMI [kg/m2] 29.7 (26.8–32.2) 29 (26.8–32) 30 (26.8–32.5) 0.73
Obesity, n (%) 12 (50.0) 3 (33.3) 9 (60.0) 0.99
HbA1c (%) 8.2 (7.8–8.6) 8.4 (8–9.7) 8.2 (7.6–8.4) 0.11
Creatinine [µmol/L] 81.2 (69.6–92) 75 (69.1–82) 85 (76.2–99.2) 0.1
TG [mmol/L] 2.4 (1.4–2.9) 2.9 (1.6–3.1) 1.9 (1.2–2.6) 0.14
TC [mmol/L] 5.4 (4.4–6.1) 5.2 (4.8–6.2) 5.5 (4.2–5.9) 0.77
LDL-C [mmol/L] 3.1 (2.3–3.8) 2.3 (1.9–3.7) 3.2 (2.4–3.8) 0.24
HDL-C [mmol/L] 1.2 (1.1–1.4) 1.2 (1.1–1.3) 1.2 (1–1.4) 0.82
CRP [mg/L] 3.3 (1–6.6) 1.1 (0.7–4) 4.2 (1.5–7.5) 0.06
AST [IU/L] 21.5 (18.5–29) 19 (18–33) 23 (20–26) 0.73
ALT [IU/L] 37 (27–48) 38 (36–45) 34 (25–49) 0.48
Leucocytes [× 109/L] 6.9 (6–8.7) 7.2 (6.3–9.9) 6.5 (5.8–8.6) 0.24
Erythrocytes [× 109/L] 4.8 (4.6–5.1) 5 (4.9–5.2) 4.6 (4.5–5.1) 0.11
Haemoglobin [g/dL] 14.7 (13.7–15.6) 14.9 (14.7–15.9) 14 (13.5–15) 0.06
Haematocrit (%) 43.7 (41–45.3) 44.1 (43.8–45.9) 42.3 (40.5–44.6) 0.08
Platelets [× 109/L] 220.5 (196.5–253) 222 (187–231) 219 (197–274) 0.52
*Continuous variables are summarised as medians (IQRs), qualitative variables are presented as the number (percentages)
ALT — alanine transaminase; AST — aspartate transaminase; BMI — body mass index; CRP — C-reactive protein; DPP-4 — dipeptidyl peptidase-4;  
HbA1c — glycosylated haemoglobin; HDL-C — high-density lipoprotein cholesterol; IQR — interquartile range; LDL-C — low-density lipoprotein cholesterol; 
SU — sulfonylurea; TC — total cholesterol; TG — triglycerides
Figure 1. Composition of the bacterial community at the phylum — L2 (A) and class — L3 (B) levels for linagliptin and SU patients 





























No significant differences were observed between 
groups in ANCOM results for phylum, order, family, 
genus or species at baseline.
No differences in within-sample phylotype richness 
and evenness (alpha diversity) metrics were detected 
between groups. Shannon diversity (p = 0.14), Pielou’s 
measure of evenness (p = 0.16), observed OTUs (p = 0.10) 
and Faith’s phylogenetic diversity (p = 0.18) did not 
differ between linagliptin and SU samples (Figure 2). 
Linagliptin and SU samples did not show statisti-
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Figure 2. Pairwise alpha diversity analysis of linagliptin and sulfonylurea (SU) groups before and after treatment intensification. 
Differences in alpha diversity were measured by Shannon index (A), Pielou’s measure of species evenness (B), observed OTUs (C) 



























































































cally differences in any evaluated distance metrics: 
unweighted UniFrac (p = 0.39), weighted UniFrac 
(p = 0.60), Bray-Curtis (p = 0.78) and Jaccard (p = 0.39). 
Moreover linagliptin and SU patients were not sepa-
rated or clustered according to PCoA of beta diversity 
metrics (Figure 3).
The two groups shared 397 OTUs, whereas 77 
OTUs were unique to the linagliptin group and 89 were 
unique to the SU group.
Bacterial profile after optimisation  
of treatment
After 4 weeks of linagliptin treatment, ANCOM 
results showed no changes in taxa in L2–L7 compared 
with baseline. The same held true for pairwise alpha 
diversity, where differences in Shannon diversity 
(p = 0.59), Pielou’s measure of evenness (p = 0.68), 
observed OTUs (p = 0.77) and Faith’s phylogenetic 
diversity (p = 0.51) were not statistically significant 
(Figure 2). Moreover, after treatment intensification, 
unweighted UniFrac (p = 0.99, weighted UniFrac 
(p = 0.93), Bray-Curtis (p = 0.98) and Jaccard (p = 0.99) 
distances were also not significant (Figure 3). After 
treatment with linagliptin, we observed 43 new OTUs 
while 58 OTUs present at baseline were lost.
After optimisation of therapy in the SU group, we 
did not observe changes in taxa in L2–L7, compared 
with baseline, in the ANCOM analysis. We did not dem-
onstrate changes in alpha diversity metrics (Shannon di-
versity, p = 0.19; Pielou’s measure of evenness, p = 0.21; 
observed OTUs, p = 0.42; and Faith’s phylogenetic 
diversity, p = 0.65; Figure 2) or beta diversity distances 
(unweighted UniFrac, p = 0.99; weighted UniFrac, 
p = 0.99; Bray-Curtis, p = 0.99; and Jaccard, p = 0.99; 
Figure 3). After treatment, we observed 50 new OTUs 
while 37 OTUs present at baseline were lost.
Continuous glucose monitoring 
Continuous glucose monitoring data were collected 
before and after optimisation of treatment in 21 patients. 
The median glucose level in the linagliptin group (n = 9) 
was 178 (171–190) mg/dL at baseline and 166 (157–174) 
mg/dL after intensification (p = 0.02). In patients in the SU 
group with available data (n = 12), the median glucose 
level was 168 (159.5–190.5) mg/dL at baseline and 144.5 
(131.5–154) mg/dL at follow-up (p = 0.015).
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Post-hoc power analysis (sample size calculation)
Based on our results, we determined that compar-
ing the SU group with the linagliptin group before 
intensification, we need at least 43 samples per group 
to achieve 0.8 statistical power with the 0.05 signifi-
cance level. As for pre and post-treatment samples, the 
necessary sample size to achieve desired power at 
desired significance level is at least 95 patients for the 
linagliptin group, and at least 53 patients for SU group.
Discussion
To our knowledge, this is the first study to compare 
microbiota before and after the addition of linagliptin 
to current treatment in patients with T2DM or HNF1A-
-MODY. Although the analysis failed to show differences 
in microbiotal composition after treatment with either 
the DPP-4 inhibitor or SU intensification, our study 
was performed on a very small number of patients, in 
linagliptin group there were only nine patients.
The study was underpowered. No statistical me-
thods were used to predetermine sample size and the 
final number of patients was limited. Post-hoc analysis 
revealed that much larger groups and need to detected 
differences between group. 
The small sample size was at least partially due to 
the limitations on patients and requirement for stool 
samples imposed by the study protocol, which may 
have discouraged patient participation. In addition, 
due to expected difficulties with longer-term patient 
compliance, the study was designed to have a relatively 
Figure 3. PCoA 2D plots of beta diversity analysis of linagliptin and sulfonylurea (SU) patients before and after treatment intensi-
fication. Beta diversity was measured by unweighted UniFrac distances (A), weighted UniFrac distances (B), Jaccard distances (C) 
and Bray-Curtis distances (D). Permutational multivariate analysis of variance (PERMANOVA) was performed to analyse statistical 
significance. Paired samples are connected with lines. Red lines represent linagliptin group and blue lines represent SU group. 
Rhombus represent pre-treatment intensification samples and rings represent post-treatment intensification samples
Axis 2 (11.52%) Axis 2 (16.77%)
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short follow-up period (4 weeks). We cannot exclude 
that differences in microbiotal composition would 
be observed during longer follow-up. Further stud-
ies should be conducted to examine and confirm this 
hypothesis-generating study. Of note, previous animal 
studies using DPP-4 inhibitors reported some changes 
in colonic microbiota after 8–12 weeks, although the 
results were equivocal [13–16]. 
So far, the effects of three DPP-4 inhibitors (vilda-
gliptin, sitagliptin and saxagliptin) on microbiota have 
been investigated in animal models [13–16], but there 
are no previous animal or human studies on the effects 
of alogliptin or linagliptin on gut microbiota. Olivares 
et al. reported a reduction in genus Oscillibacter spp. 
and unclassified Ruminococcaceae (OTU 241) follow-
ing 8 weeks of vildagliptin use [13]. Zhang et al. also 
observed changes in bacterial flora after administration 
of vildagliptin in diabetic rats for 12 weeks [14]. Yan 
et al. showed changes in microbiota composition in 
diabetic rats after the administration of sitagliptin for 
12 weeks, with an increase in the relative abundance 
of Bacteroidetes and Proteobacteria, and a decrease 
in Firmicutes after treatment [15]. Zhang et al. also 
reported a higher relative abundance of Bacteroidetes 
and lower abundance of Firmicutes after treatment with 
vildagliptin. Both sitagliptin [15] and vidagliptin [14] 
have been shown to increase the amount of butyrate-
producing bacteria. Finally, Wang et al. observed an 
increase in the relative abundance of Firmicutes after 
administration of saxagliptin for 8 weeks [16], in con-
trast to the studies of Yan et al. (sitagliptin) [15] and 
Zhang et al. (vildagliptin) [14].
One cannot exclude that the lack of effect on 
colonic microbiota in our study was due the use of 
linagliptin, which has not yet been evaluated for effects 
on colonic microflora in animals. The observed effect of 
linagliptin on microbiota across patients in our study 
was heterogeneous, however, we failed to determine 
factors associated with this phenomenon, possible 
due to limited patients number in subgroups. In more 
numerous subgroups we could notice different trends, 
for example in HNF1A and T2DM patients. Further 
studies could reveal potential features or phenotypes 
responsible for different trends in individual patients. 
Furthermore, although patients were encouraged 
to follow general dietary recommendations for diabe-
tes before the study, our results could also have been 
influenced by individual variations in diet composition, 
food preparation methods or quality of ingredients. 
For instance, one could speculate that individuals 
who could afford linagliptin (which is not reimbursed) 
could also afford better quality food. It has been re-
ported that microbiota composition is predominately 
modified by diet [12, 28, 29]. In mice, changes in diet 
account for 57% of the variation in gut microbiota and 
genetic factors for 12% [30]. One cannot exclude that 
changes in diet composition attenuated the effect of 
DPP-4 inhibition. 
Conclusions
We did not observe major differences in the struc-
ture and composition of the colonic bacterial flora after 
treatment with linagliptin in our preliminary study. 
However, the study was underpowered, and due to 
the small study size and short follow-up period, we 
cannot exclude some effect of linagliptin on the colonic 
microbiota. Further longitudinal studies based on larger 
populations should be performed to determine whether 
incretin-based drugs, including DPP-4 inhibitors, influ-
ence the colonic bacterial flora. 
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